Changes in bronchial mucous membrane depending on the stage of COPD Source: Annual Congress 2009 - COPD: from biomarker profiling to clinical assessment Year: 2009
Clinical-morphological changes in bronchial mucous membrane according to the III-IV COPD stages Source: Annual Congress 2011 - COPD diagnosis Year: 2011
Increased expression of SARS-CoV-2 (Covid-19) adhesion sites on type II pneumocytes, small airway epithelium, and alveolar macrophages in smokers and patients with COPD Source: Virtual Congress 2021 – Mechanistic pathways in chronic and new lung diseases Year: 2021
Collagen I, III and IV content in airways and lung parenchyma of COPD patients Source: Annual Congress 2010 - Proteases and the matrix Year: 2010
Decreased expression of TGFβ1 type II receptor in bronchial glands of smokers with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 98s Year: 2004
Parameters of sIgE and sIgG4-autoAbs to lung elastin, collagen type III and myosin in bronchial asthma in association with chronic infection. Source: International Congress 2019 – Understanding the mechanisms underlying airway diseases Year: 2019
Collagen type III content in large airways and distal lung of fatal asthma Source: Eur Respir J 2005; 26: Suppl. 49, 279s Year: 2005
Effects of static stretch on secretory function and morphology in alveolar epithelial type II cells Source: Annual Congress 2008 - Border patrol: the alveolar barrier in lung injury Year: 2008
The influence of roflumilast on the IV-type collagen level in patients with III stage COPD Source: Annual Congress 2012 - Lung injury and repair: reactive oxygen species and beyond Year: 2012
COPD assessment: I, II, III, IV and/or A, B, C, D Source: Eur Respir J 2014; 43: 949-950 Year: 2014
Features of mucous membrane changes of bronchial tree at patients with COPD Source: Annual Congress 2011 - COPD diagnosis Year: 2011
Type I and III collagen protein precursors in the airways of smokers and COPD-patients Source: Annual Congress 2008 - Structural remodelling in COPD Year: 2008
Changes of urotensin II in induced sputum and plasma of patients with COPD and asthma Source: Eur Respir J 2006; 28: Suppl. 50, 672s Year: 2006
Hyperoxia reversibly inhibits the transdifferentiation of alveolar type II (ATII) cells to alveolar type I (ATI) cells Source: Annual Congress 2005 - Cellular and molecular approaches to lung injury research Year: 2005
TGF-β1 type II receptor (TGF-βRII) expression in pulmonary arteries of patients with severe COPD Source: Eur Respir J 2005; 26: Suppl. 49, 96s Year: 2005
Effects of tiotropium on lung volumes during exercise in GOLD stage II to IV COPD patients Source: Eur Respir J 2006; 28: Suppl. 50, 171s Year: 2006
Characteristics of bronchial mucous membrane morphological picture in bronchial asthma depending on its duration Source: Eur Respir J 2004; 24: Suppl. 48, 96s Year: 2004
The role of cell lines in modelling the type II pneumocyte in interstitial lung disease Source: Virtual Congress 2020 – Human ex vivo models of interstitial lung disease Year: 2020
Type XIX collagen quantified in serum targeting the anti-tumorigenic NC1 domain is elevated in early and late stage lung carcinoma patients and COPD Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer Year: 2020
Increased expression of ACE2, the SARS-CoV-2 entry receptor, in alveolar and bronchial epithelium of smokers and COPD subjects Source: Eur Respir J, 56 (2) 2002378; 10.1183/13993003.02378-2020 Year: 2020